Bone Biologics Corp Files 8-K
Ticker: BBLGW · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $832,009, $846,288 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, filing
Related Tickers: BBLG
TL;DR
BBLG filed an 8-K on 12/13/24, mostly financial docs.
AI Summary
On December 13, 2024, Bone Biologics Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure of material information. No specific new events, transactions, or financial figures beyond the filing itself are detailed in the provided text.
Why It Matters
This 8-K filing serves as an official record of Bone Biologics Corporation's disclosures to the SEC, providing transparency to investors about the company's financial status and other material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, not indicating any immediate or significant new risks.
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- December 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40899 (identifier) — SEC File Number
- 42-1743430 (identifier) — IRS Number
FAQ
What is the primary purpose of this 8-K filing by Bone Biologics Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 13, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 13, 2024.
In which state is Bone Biologics Corporation incorporated?
Bone Biologics Corporation is incorporated in Delaware.
What is the SEC file number for Bone Biologics Corporation?
The SEC file number for Bone Biologics Corporation is 001-40899.
What is the IRS number for Bone Biologics Corporation?
The IRS number for Bone Biologics Corporation is 42-1743430.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-13 17:05:20
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
- $832,009 — & Co., LLC, dated September 27, 2024 to $832,009. The Company previously sold approximat
- $846,288 — e Company previously sold approximately $846,288 of shares of Common Stock pursuant to t
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex5-1.htm (EX-5.1) — 18KB
- ex5-1_001.jpg (GRAPHIC) — 37KB
- ex5-1_002.jpg (GRAPHIC) — 20KB
- 0001493152-24-050025.txt ( ) — 364KB
- bblg-20241213.xsd (EX-101.SCH) — 4KB
- bblg-20241213_def.xml (EX-101.DEF) — 29KB
- bblg-20241213_lab.xml (EX-101.LAB) — 36KB
- bblg-20241213_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On December 13, 2024, Bone Biologics Corporation (the "Company") filed a prospectus supplement to update the maximum amount of shares the Company is eligible to sell under the At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, dated September 27, 2024 to $832,009. The Company previously sold approximately $846,288 of shares of Common Stock pursuant to the Sales Agreement pursuant to a prior prospectus supplement dated September 27, 2024. A copy of the legal opinion as to the legality of the $832,009 of shares of Common Stock issuable under the Sales Agreement and covered by the prospectus supplement is filed as Exhibit 5.1 attached hereto. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Harter Secrest & Emery LLP 23.1 Consent of Harter Secrest & Emery LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: December 13, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer